How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Bronchial Spasm Treatment Market
- By Drug Class: Beta-2 Adrenergic Agonists, Anticholinergics, Methylxanthines, Corticosteroids, Leukotriene Receptor Antagonists
- By Route of Administration: Inhalation, Oral, Intravenous, Nebulization
- By End User: Hospitals, Clinics, Home Care Settings, Ambulatory Surgical Centers
- By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Bronchitis, Allergic Bronchospasm
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Beta-2 Adrenergic Agonists leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Bronchial Spasm Treatment Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Route of Administration 4
End User 4
Indication 4
Companies profiled
GlaxoSmithKline plc
AstraZeneca plc
Novartis AG
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now part of Viatris)
Boehringer Ingelheim GmbH
Pfizer Inc.
Sanofi S.A.
Chiesi Farmaceutici S.p.A.
Sun Pharmaceutical Industries Ltd.
Cipla Limited
Sandoz International GmbH (a Novartis division)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Boehringer Ingelheim GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Chiesi Farmaceutici S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sun Pharmaceutical Industries Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cipla Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sandoz International GmbH (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Lupin Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Zhejiang Huahai Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Hikma Pharmaceuticals PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,133M by 2033 · 10.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Beta-2 Adrenergic Agonists38.4
- Anticholinergics12.6
- Methylxanthines19.9
- Corticosteroids17.9
- Leukotriene Receptor Antagonists11.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$633.0M → $1,444M · 10.9%
Europe$441.2M → $1,036M · 11.3%
Asia Pacific$402.8M → $786.4M · 8.7%
Latin America$249.4M → $534.9M · 10.0%
Middle East and Africa$191.8M → $442.4M · 11.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.022026
10.042027
10.052028
10.072029
10.082030
10.072031
10.092032
10.102033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- GlaxoSmithKline plc14.5
- AstraZeneca plc23.2
- Novartis AG6.6
- Teva Pharmaceutical Industries Ltd.11.1
- Mylan N.V. (now part of Viatris)10.9
- Boehringer Ingelheim GmbH5.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class21.1%
Route of Administration20.6%
End User29.0%
Indication29.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe24.4
- Asia Pacific18.5
- Latin America12.6
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | 95 | 96 | 87 | 88 | 87 | 88 | 90 |
| AstraZeneca plc | 93 | 86 | 69 | 78 | 83 | 84 | 82 |
| Novartis AG | 72 | 72 | 73 | 86 | 73 | 71 | 75 |
| Teva Pharmaceutical Industries Ltd. | 63 | 59 | 66 | 59 | 80 | 77 | 67 |
| Mylan N.V. (now part of Viatris) | 68 | 61 | 54 | 58 | 56 | 76 | 62 |
| Boehringer Ingelheim GmbH | 58 | 52 | 69 | 63 | 66 | 67 | 63 |
| Pfizer Inc. | 59 | 52 | 47 | 65 | 60 | 62 | 58 |
| Sanofi S.A. | 47 | 47 | 44 | 35 | 36 | 39 | 41 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- GlaxoSmithKline plc
- AstraZeneca plc
- Novartis AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| GlaxoSmithKline plc | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| AstraZeneca plc | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Novartis AG | ◐ | − | − | ◐ | ✓ | ✓ |
| Teva Pharmaceutical Industries Ltd. | ◐ | − | ◐ | − | ◐ | ◐ |
| Mylan N.V. (now part of Viatris) | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Boehringer Ingelheim GmbH | − | − | − | ◐ | − | − |
| Pfizer Inc. | − | − | ◐ | ◐ | ◐ | ✓ |
| Sanofi S.A. | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1GlaxoSmithKline plc90
2AstraZeneca plc82
3Novartis AG75
4Teva Pharmaceutical Industries Ltd.67
5Boehringer Ingelheim GmbH63
6Mylan N.V. (now part of Viatris)62
7Pfizer Inc.58
8Sanofi S.A.41
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
GlaxoSmithKline plcAstraZeneca plc
Challenger2
Strong scale, closing on the leaders.
Novartis AGTeva Pharmaceutical Industries Ltd.
Contender3
Focused players with pockets of strength.
Mylan N.V. (now part of Viatris)Boehringer Ingelheim GmbHPfizer Inc.
Niche1
Specialists in a single segment or region.
Sanofi S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Bronchial Spasm Treatment Market — a $318M beachhead inside a $4.64B market.
Beachhead (SOM)$318Mobtainable near-term
Serviceable (SAM)$1.79Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Beta-2 Adrenergic Agonists
Best fit — highest urgency & budget in Drug Class.
Economic buyer81 fit
Anticholinergics
Strong fit — clear ROI and a fast path to value.
End user69 fit
Methylxanthines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Bronchial Spasm Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified25%
Evaluation12%
Closed-won5%
$11.6KCAC
$45KLTV
3.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Bronchial Spasm Treatment Market is a durable-growth opportunity — $6.14B by 2033, compounding at 7.9%.
TAM · 2025$3.33Btoday
TAM · 2033$6.14Bforecast
CAGR7.9%2027–2033
Cumulative$41.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.14BTotal addressable market
SAM$2.27BServiceable available market
SOM$465MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.9% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.14BLarge & growingTAM by 2033 at 7.9% CAGR
$2.27BServiceable nowreachable with today’s model
$465MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.79BBear5.2% CAGR
$6.14BBase7.9% CAGR
$7.86BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Bronchial Spasm Treatment Market — a $3.08B market by 2033. Plan: grow share from 9.3% to 14.5%.
Market size · 2033$3.08Btotal addressable
Market CAGR8.7%2027–2033
Target share14.5%from 9.3% today
Revenue ambition$447Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.3% | 14.5% | Behind |
| Revenue | $275M | $447M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 33.5% | 45.8% | At risk |
| Customer retention | 84.5% | 95.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $64M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Bronchial Spasm Treatment Market conversation — a $3.70B market you can size, segment and defend in minutes.
Market size · 2033$3.70Btotal opportunity
Growth5.8%CAGR to 2033
Addressable buyers1,247+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 4 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
GlaxoSmithKline plcAstraZeneca plcNovartis AGTeva Pharmaceutical Industries Ltd.Mylan N.V. (now part of Viatris)Boehringer Ingelheim GmbHPfizer Inc.Sanofi S.A.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Bronchial Spasm Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Bronchial Spasm Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Bronchial Thermoplasty Catheter Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportBronchitis Drugs Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportBronchoscope Video Endoscope Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportBronchoscopic Devices Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBronchoscopy Devices Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBronchoscopy Instruments for Children Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBronchospasm Drug Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBronopol Wettable Powder Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportBronze Casting and Forging Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBronze Nuts Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportBronze Plating Solution Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBronze Sintered Power Filter Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.